Business Context and Reporting Period
Altimmune, Inc. filed this Form 8-K on September 28, 2021, to disclose positive results from a Phase 1 clinical trial of its investigational drug pemvidutide (ALT-801). The company is a biopharmaceutical firm focused on developing therapies for metabolic diseases, including obesity and non-alcoholic steatohepatitis (NASH).
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding clinical trial results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Results
The primary material event is the announcement of positive 12-week results from a multiple ascending dose (MAD) study in overweight and obese volunteers. Key findings include:
- Weight Loss Efficacy: Subjects receiving pemvidutide achieved mean weight losses of 4.9% (1.2 mg), 10.3% (1.8 mg), and 9.0% (2.4 mg), compared to 1.6% in the placebo group.
- Dose Response: The 1.8 mg cohort showed the highest efficacy, with 100% of subjects losing at least 5% of body weight and 55% losing at least 10%.
- Safety Profile: Side effects were mild to moderate with no serious or severe treatment-emergent adverse events. There were zero discontinuations due to adverse events across all treatment groups.
- Secondary Measures: Favorable trends were observed in blood pressure, serum lipids, and insulin resistance (HOMA-IR).
Outlook, Management Commentary, and Risks
Management outlined a development plan based on these results:
- NASH Development: An Investigational New Drug (IND) application for NASH has cleared FDA review. A 12-week trial to measure liver fat reduction is expected to commence soon, followed by a 52-week Phase 2 biopsy-driven NASH trial in the first half of 2022.
- Obesity Development: The company intends to file a second IND application for obesity in the fourth quarter of 2021, with plans to initiate a 48-week Phase 2 obesity trial in the first half of 2022.
- Diabetes Studies: A trial for glucose control in type 2 diabetes patients is anticipated to start in the fourth quarter of 2021.
- Risks: While tolerability decreased at higher dose levels, no hyperglycemia or heart rate increases were observed. One patient experienced elevated liver enzymes that resolved after a dosing pause.
Investor Verification Checklist
- Verify the timeline for the initiation of the Phase 2 NASH and obesity trials scheduled for 2022.
- Monitor the status of the second IND application for obesity expected in Q4 2021.
- Review upcoming financial filings (10-Q or 10-K) for cash burn rates and liquidity, as this 8-K contains no financial data.
- Assess the long-term safety profile as the company moves from Phase 1 to Phase 2 trials with larger patient populations.